A crossover study on lipid and weight changes associated with olanzapine and risperidone

Psychopharmacology

Volumn 183, Issue 3, 2005, Pages 383-386

  Su, Kuan Pin ^a,b   Wu, Po Lun ^a   Pariante, Carmine M ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atypical antipsychotics; Crossover; Diabetes; Hyperlipidaemia; Olanzapine; Risperidone

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; PRIORITY JOURNAL; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CROSS-OVER STUDIES; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 27844500182     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0205-2     Document Type: Article

References (23)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601
2. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598-604
3. Castelli WP (1986) The triglyceride issue: a view from Framingham. Am Heart J 112:432-437
4. Ghaeli P, Dufresne RL (1999) Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 19:1099-1101
5. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372
6. Itoh T, Horie S, Takahashi K, Okubo T (1996) An evaluation of various indices of body weight change and their relationship with coronary risk factors. Int J Obes Relat Metab Disord 20:1089-1096
7. Koro CE, Meyer JM (2005) Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 6:148-157
8. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026
9. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986) Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2:933-936
10. McIntyre RS, McCann SM, Kennedy SH (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46:273-281
11. Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749
12. Melkersson KI, Dahl ML, Hulting AL (2004) Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 175(1):1-6
13. Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425-433
14. Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1-17
15. O'Neil MJ, Smith A, Heckelman PE, Kinneary JF, Budavari S (2001) The Merck index: an encyclopedia of chemicals, drugs and biologicals, 13 edn. Merck & Co., Whitehouse Station, NJ
16. Osser DN, Najarian DM, Dufresne RL (1999) Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767-770
17. Ried LD, Renner BT, Bengtson MA, Wilcox BM, Acholonu WW Jr (2003) Weight change after an atypical antipsychotic switch. Ann Pharmacother 37:1381-1386
18. Su KP, Shen WW, Huang SY (2001) Lipid abnormalities induced by novel antipsychotic drugs. Drug Saf 24:1017-1018
19. Su KP, Shen WW, Chuang CL, Chen KP, Chen CC (2003) A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophr Res 59:93-94
20. Van Gaal LF, Zhang A, Steijaert MM, De Leeuw IH (1995) Human obesity: from lipid abnormalities to lipid oxidation. Int J Obes Relat Metab Disord 19(Suppl 3):S21-S26
21. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865
22. Wu BL, Lane HY, Su KP. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus. Psychiatry Clin Neurosci, in press
23. Yanovski JA, Yanovski SZ (1999) Recent advances in basic obesity research. JAMA 282:1504-1506